Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...
Ozanimodâ–¼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
However, the sector faces another kind of risk, with a new administration in charge in Washington.
Zacks.com on MSN9h
AbbVie Inks a Deal With Neomorph for Molecular Glue DegradersAbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based ...
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback